Funders › CA › Pediatric Cancer Research Foundation › 2022
Grants paid by Pediatric Cancer Research Foundation, tax year 2022
EIN 95-3772528 · Irvine, CA · Form 990, Schedule I
In tax year 2022, Pediatric Cancer Research Foundation (EIN 95-3772528) reported 16 grants paid totaling $1,929,700. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2022
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2022 | New York Medical College Valhalla, NY | A | $900,000 | paid | PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NYMC | 202322719349302127 |
| 2022 | University of Texas Md Anderson Cancer Center Houston, TX | A | $125,000 | paid | COMBINING A NOVEL DENDRITIC CELL VACCINE WITH CHECKPOINT BLOCKADE FOR OSTEOSARCOMA THERAPY | 202322719349302127 |
| 2022 | Children's Hospital of Philadelphia Philadelphia, PA | A | $125,000 | paid | PRECISION MEDICINE TO EXPLOIT BCL2-FAMILY SURVIVAL DEPENDENCIES IN NEUROBLASTOMA | 202322719349302127 |
| 2022 | University of California San Francisco San Francisco, CA | A | $115,000 | paid | MODULATING THE IMMUNE MICROENVIRONMENT IN PEDIATRIC ACUTE MYELOID LEUKEMIA | 202322719349302127 |
| 2022 | Ann & Robert Lurie Children's Hospital Chicago, IL | A | $75,000 | paid | INTRANASAL DELIVERY OF TARGETING NANOLIPOSOMAL THERAPEUTICS FOR PEDIATRIC GLIOMA | 202322719349302127 |
| 2022 | Dana-Farber Cancer Institute Boston, MA | A | $75,000 | paid | PROSPECTIVE VALIDATION OF A PROGNOSTIC LIQUID BIOPSY APPROACH FOR PEDIATRIC EWING SARCOMA | 202322719349302127 |
| 2022 | University of Alabama at Birmingham Birmingham, AL | A | $75,000 | paid | ENHANCEMENT OF IMMUNOVIROTHERAPY WITH DIRECTED DRUG DELIVERY FOR TREATMENT OF PEDIATRIC HIGH-GRADE GLIOMA | 202322719349302127 |
| 2022 | Stanford University Palo Alto, CA | A | $75,000 | paid | DEVELOPMENT OF SMALL MOLECULES TO TARGET CRED:CBP INTERACTION FOR TREATMENT OF AML | 202322719349302127 |
| 2022 | Baylor College of Medicine Houston, TX | A | $75,000 | paid | OFF-THE-SHELF COMBINATION CANCER IMMUNOTHERAPY WITH ONCOLYTIC ADENO-IMMUNOTHERAPY AND CAR NK CELL THERAPY FOR PEDIATRIC SARCOMA | 202322719349302127 |
| 2022 | UCLA Foundation Los Angeles, CA | A | $55,000 | paid | RESEARCH INTO MULTIDISCIPLINARY APPROACH TO SIGNIFICANTLY AND POSITIVELY IMPROVE THE QUALITY OF LIFE AND QUALITY OF CARE FOR CHILDREN AND YOUNG PEOPLE WITH CANCER | 202322719349302127 |
| 2022 | Lucille Packard Children's Hospital Palo Alto, CA | A | $50,000 | paid | EFFECTIVE THERAPY FOR PEDIATRIC HIGH-GRADE GLIOMAS | 202322719349302127 |
| 2022 | Texas Children's Hospital Houston, TX | A | $50,000 | paid | DEVELOPING A SENSITIVE METHOD FOR CIC FUSION GENE DETECTION IN SARCOMAS BY CUSTOMIZED GENOMIC SEQUENCING | 202322719349302127 |
| 2022 | Hope for Henry Foundation Washington, DC | A | $50,000 | paid | REINVENTING HOW HOSPITALS CARE FOR SERIOUSLY ILL CHILDREN AND THEIR FAMILIES THROUGH INNOVATIVE PROGRAMS THAT ENTERTAIN, REDUCE STRESS, AND EMPOWER CHILDREN TO BE ACTIVE PARTICIPANTS IN THEIR OWN CARE. | 202322719349302127 |
| 2022 | Seattle Children's Hospital Seattle, WA | A | $30,000 | paid | DEVELOPMENT OF TUNABLE ON-OFF CAR T CELLS FOR SAFE AND DURABLE TUMOR CONTROL | 202322719349302127 |
| 2022 | Massachusetts General Hospital Boston, MA | A | $29,700 | paid | OPTIMIZING CAR T CELL IMMUNOTHERAPY FOR PEDIATRIC RHABDOMYOSARCOMA | 202322719349302127 |
| 2022 | Ann & Robert Lurie Children's Hospital Chicago, IL | A | $25,000 | paid | IMMUNOTHERAPY FOR DIPG | 202322719349302127 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.